MEDraysintell Releases a New Report Covering the Most Promising Radiopharmaceuticals
Most promising radiopharmaceuticals on the market by 2024-2026
Louvain-la-Neuve, Belgium, February 03, 2018 --(PR.com)-- MEDraysintell releases a new report covering the most promising radiopharmaceuticals (radiodiagnostics, radiotherapeutics and radiotheranostics) currently in clinical stage development which have the highest chances to reach the market by 2024-2026.
This new report covers 35 products along with the profile of the 27 companies developing these products, and aims to advice on the potential for investments, merger and acquisitions (M&A), technology and market development existing in this healthcare technology.
Detailed table of contents and sample pages available upon request at peg@medraysintell.com Several new radiopharmaceuticals will enter the market in the coming years fueling the growth of the global Nuclear Medicine market which was valued at some US$ 4.5 billion in 2016 and is expected to reach US$ 26 billion in 2030, with radiotherapeutics to represent 60% of the nuclear medicine market by 2030 compared to 12% in 2016.
Most of the new products that are expected to reach the market by 2024-2026 will be labelled with Fluorine-18, Gallium-68 or Technetium-99m for the radiodiagnostics and with Lutetium-177 and Iodine-131 for the radiotherapeutic products.
This report is an excerpt of the full report entitled “Nuclear Medicine World Market Report & Directory Edition 2017” published in July 2017, and will be a real asset for the healthcare industry or for the financial community (investors, investment bankers and M&A professionals) to support their audit and to make informed decisions with unbiased and factual intelligence from experts.
MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,100 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com
This new report covers 35 products along with the profile of the 27 companies developing these products, and aims to advice on the potential for investments, merger and acquisitions (M&A), technology and market development existing in this healthcare technology.
Detailed table of contents and sample pages available upon request at peg@medraysintell.com Several new radiopharmaceuticals will enter the market in the coming years fueling the growth of the global Nuclear Medicine market which was valued at some US$ 4.5 billion in 2016 and is expected to reach US$ 26 billion in 2030, with radiotherapeutics to represent 60% of the nuclear medicine market by 2030 compared to 12% in 2016.
Most of the new products that are expected to reach the market by 2024-2026 will be labelled with Fluorine-18, Gallium-68 or Technetium-99m for the radiodiagnostics and with Lutetium-177 and Iodine-131 for the radiotherapeutic products.
This report is an excerpt of the full report entitled “Nuclear Medicine World Market Report & Directory Edition 2017” published in July 2017, and will be a real asset for the healthcare industry or for the financial community (investors, investment bankers and M&A professionals) to support their audit and to make informed decisions with unbiased and factual intelligence from experts.
MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!
MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,100 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com
Contact
MEDraysintell
Paul-Emmanuel Goethals
+32 491 080 968
www.medraysintell.com
Richard Zimmermann
+33 6 82 80 06 00
Paul-Emmanuel Goethals
+32 491 080 968
www.medraysintell.com
Richard Zimmermann
+33 6 82 80 06 00
Contact
Categories